Comprehensive India pharma market report to be launched at CPhI India 2014
Report to analyse trends from leading Indian pharma players and forecast new markets and growth areas in a region predicted by analysts to reach US$45 billion by 2020
CPhI India, organised by UBM Live, will be releasing a comprehensive India pharma market report at CPhI India 2014, which takes place 2-4 December 2014 in Mumbai. The report, compiled with the help of research partner Global Business Reports, will include thought-provoking analysis from key industry players – e.g. Cipla, Piramal, Sun, Lupin, Aurobindo and Biocon, Government bodies (IBEF/Pharmexcil) and will explore new growth areas emerging across the country.
Now the tenth largest economy in the world and with global exports of around US$15bn over the last 12 months, India is an innovation hub and a well-known focal point of the pharmaceutical industry; McKinsey and Company forecast a staggering total value of US$45bn by 2020. Around 220 countries are sourcing pharma products from India, with India’s top 20 pharmaceutical companies contributing almost two-thirds of the country’s total exports.
Those companies are further expected to increase capital expenditure by 40% to in excess of $8.3bn by 2017-18. India is constantly looking to increasingly match high quality Western standards, while maintaining lower manufacturing costs, showcasing the Indian pharma market's unique position and providing an optimum investment platform for international companies.
The CPhI India report will feature a robust analysis of the Indian pharma market and include significant contributions from 98 companies and all major Indian manufacturers, evaluating conditions for both foreign and domestic companies. Printed copies of the detailed 100+ page report will be available at CPhI India.
CPhI India will take place at the Bombay Convention and Exhibition Centre, Mumbai from 2 – 4 December 2014 and is expected to be attended by nearly 30,000 industry executives from more than 95 countries. CPhI will co-locate with P-MEC India, ICSE India and BioPh in a key global event that is the perfect meeting place to network, observe trends and enhance new business opportunities. A series of technical seminars will take place throughout the show, providing detailed insights into current trends, issues and developments surrounding the pharma community, alongside the CPhI Pharma Awards India. A mobile app will be available to assist with navigation throughout CPhI India and provide easier access to all areas of the event.
Another new initiative is the introduction of the CPhI Global Angels charity campaign, which was launched earlier this year at CPhI Worldwide. It is being rolled out across CPhI’s global portfolio and calls on the pharma community to lend its support to this global charity that is transforming disadvantaged communities around the world.
'With the highest number of USFDA approved facilities outside the US, it is unsurprising that India has seen a huge growth in the number of exports. India’s economy is thriving as the demand for generics is on the rise and companies are looking to drive down manufacturing costs. India is well positioned to accommodate increased demand, providing expertise in development and manufacturing,' said Chris Kilbee, Group Director Pharma at UBM Live.
'This is an amazing time for the CPhI community to gather in Mumbai during the CPhI India, a world class pharma event that continues to provide an essential platform for international and domestic suppliers & buyers to break into the market. There has never been a better time to invest in such a dynamic and thriving economy and we look forward to another successful CPhI India.'
